ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Varmus To Cut Five Percent From Cancer Centers As NCI Adjusts To “Financial disaster”

May 6, 2011

ORI Finds St. Mary’s Data Managers Falsified Data In BCPT

September 8, 1995

IARC Finds Betel Quid, Areca Nut Chewing Causes Cancer

September 26, 2003

Reinventing NCI: clinical Trials report Calls for Study Section, increased Funding For Cooperative Groups

October 3, 1997

ACCC To Ask Congress To Earmark Appropriations For Construction Of Community Cancer Centers

January 17, 1975

The Cancer Letter takes summer publication break, back Sept. 12.

August 8, 2003